
India's air pollution strategy needs atmanirbharta
Industry collaborations with Indian R&D institutions are now being actively promoted — something that was missing in the past. A key example is the Anusandhan National Research Foundation, which signals the government's commitment to strengthening research and innovation with industrial contribution. Yet, the air quality crisis persists.
We often come across headlines about ambitious air quality projects where a small country attracts international funding, ties up with well-known and well-funded Indian institutions and initiates studies on India's air pollution. This raises two related questions: Why are developed countries, with no direct stake in India's air quality, so keen on studying it? Two, why are Indian institutes not leading such research? These concerns become even more pressing in the era of climate justice, and unequal climate sanctions. Recent reports of the shutdown of climate research at key US agencies under the Trump administration have raised worldwide alarm — they expose a critical vulnerability due to the over-dependence on data generated by global agencies for climate and weather forecasting. Many of our own weather, climate and air quality prediction systems rely on these data sets. The disruption is a wake-up call. Why not launch polar-orbiting satellites and gather global data to fulfil our model requirements?
India has a notable history of air quality advancements. We pioneered the National Ambient Air Quality Monitoring Programme in 1984 . Delhi's rapid transition to a CNG-based public transport fleet was another landmark. A significant scientific milestone came in 2010, when India developed its first indigenous air quality forecasting system, SAFAR (System of Air Quality and Weather Forecasting and Research), despite resistance from foreign agencies. Despite its success, however, SAFAR remained limited to just four cities.
Some Indian states are now taking commendable steps such as the rapid EV transition. India also has world-class agencies like the Earth System Science Organisation (ESSO) and India Meteorological Department (IMD). A stronger collaboration between ESSO-IMD and the Central Pollution Control Board (CPCB) could set a global benchmark in air quality management and forecasting.
This begs a question: Despite initiatives like Make in India, unspent funds, an abundance of talent, a young workforce, and openness to industry sponsorship, why are we still struggling to achieve true 'atmanirbharta'? Are our resources disproportionately funnelled into a select few institutions? Is there a gap in expertise? A majority of international collaborations or foreign funding is centred around elite institutions. Alarmingly, even some government-funded research institutions seem to be aligning with this foreign-dependent model.
The core challenge lies in the absence of an integrated air quality resource framework. A unified platform is needed to foster a science-based information system and a knowledge hub. This would empower decision-makers and the private sector to take informed action. Under the auspices of the office of the Principal Scientific Advisor, the National Institute of Advanced Studies has undertaken a study exploring a new approach of airshed management, combined with finely gridded source emissions. This initiative aims to accelerate pollution control strategies, which could also contribute to the net-zero goal. This led to envisaging the concept of a resource framework, NARFI, designed to act as a catalyst for inter-organisational collaboration, interdisciplinary research and evidence-based decision-making. Now is the time to rethink air quality strategies by scientifically integrating broader airshed factors rather than adopting city-centric approaches. We need to prioritise health-centric measures and food security. That would mean real atmanirbharta.
Beig is Chair Professor, NIAS and Founder Director, SAFAR. Nayak is Director, NIAS and Former Secretary Ministry of Earth Sciences
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Hindustan Times
an hour ago
- Hindustan Times
Keep upgrading skills to face emerging challenges: MLA advises students
LUCKNOW BJP MLA from Sarojini Nagar, Rajeshwar Singh, on Friday advised students to continuously upgrade themselves to face emerging challenges. BJP MLA, Rajeshwar Singh, at the TMS Millennia & Business Unplugged event held at The Millennium School, South City, Rae Bareli Road in Lucknow. (Sourced) 'Artificial Intelligence is transforming industries rapidly. According to global studies, by 2030, over 70% of today's jobs may cease to exist. Your biggest challenge will be to continuously upgrade your skills and adapt,' said Singh, addressing the audience. He was the chief guest at the TMS Millennia & Business Unplugged event held at The Millennium School, South City, Rae Bareli Road in the state capital. In a generous gesture towards promoting digital empowerment, the MLA donated five laptops to meritorious students of the school. Singh highlighted the turbulent global scenario, referencing the ongoing wars around the world, especially the Russia-Ukraine conflict, where over $300 billion has been spent, more than 1.5 lakh lives lost and over 10 million people displaced. 'Seeing your faces today, I am confident, the future of India is incredibly bright,' he told students. The MLA appreciated platforms like TMS and Business Unplugged for nurturing creativity, innovation and skills among students, calling them a blessed generation. Singh reflected on India's journey from Colonial oppression to becoming the world's 4th largest economy, crediting the sacrifices of past generations and the resilience of Indian families. 'Now, it is your responsibility to carry India forward. Health and environment are major challenges for your generation. Every year, over 6 million Indians die due to non-communicable and lifestyle-related diseases. Sustainable and green development is the only way forward,' he said. He emphasised the government's commitment to youth development under the leadership of Prime Minister Narendra Modi and chief minister Yogi Adityanath. Singh urged students to be vigilant in the age of misinformation, fake news and deepfakes, reminding them that: 'By 2050, machines may become more intelligent than human beings. It is essential to master technology and not become a victim of it.' Prominent among those present on the occasion included chairman of the institute, Shantanu Prakash, principal Manjulika Goswami, headmistress Priyanka Bhandari, coordinator Akanksha Sharma, admin manager Sachin Dubey, BJP leaders Shankari Singh and Tejpal Sial, among others.


Time of India
4 hours ago
- Time of India
GSK set to get $500 million from settlement of mRNA lawsuit
CureVac NV has settled a long-running patent dispute over mRNA vaccines with Pfizer and BioNTech SE in the US, which will see CureVac's former collaborator GSK receive as much as $500 million and 1% of royalties from future vaccine sales. The settlement comes as BioNTech looks to close the purchase of its former rival CureVac for about $1.25 billion. GSK will receive $370 million upfront, with another $130 million on the closing of the acquisition. Productivity Tool Zero to Hero in Microsoft Excel: Complete Excel guide By Metla Sudha Sekhar View Program Finance Introduction to Technical Analysis & Candlestick Theory By Dinesh Nagpal View Program Finance Financial Literacy i e Lets Crack the Billionaire Code By CA Rahul Gupta View Program Digital Marketing Digital Marketing Masterclass by Neil Patel By Neil Patel View Program Finance Technical Analysis Demystified- A Complete Guide to Trading By Kunal Patel View Program Productivity Tool Excel Essentials to Expert: Your Complete Guide By Study at home View Program Artificial Intelligence AI For Business Professionals Batch 2 By Ansh Mehra View Program In the wake of the race to develop Covid-19 vaccines, drugmakers launched multiple lawsuits against one another over alleged patent infringement. The litigation has spanned across Europe and the US, pitting rival vaccine manufacturers against one another in the courts. GSK worked with CureVac to develop Covid-19 vaccines but they failed, losing out to quicker, nimbler rivals. Last year, the two companies restructured their collaboration, with GSK paying CureVac up to $1.4 billion for the full rights to mRNA flu and Covid-19 vaccines it was developing with the German biotech. GSK will also receive 1% on royalties of future Pfizer-BioNTech sales of flu, Covid-19 and related combination mRNA vaccines in the US. Once BioNTech completes the purchase of CureVac, GSK will also receive 1% of royalties from future sales outside the US. Live Events While the settlement ends CureVac's litigation with Pfizer and BioNTech, it doesn't mean the same for GSK. The British drugmaker said it will continue its litigation against BioNTech and Pfizer for what it alleges is infringement of its patents.


Economic Times
4 hours ago
- Economic Times
GSK set to get $500 million from settlement of mRNA lawsuit
Live Events (You can now subscribe to our (You can now subscribe to our Economic Times WhatsApp channel CureVac NV has settled a long-running patent dispute over mRNA vaccines with Pfizer and BioNTech SE in the US, which will see CureVac's former collaborator GSK receive as much as $500 million and 1% of royalties from future vaccine settlement comes as BioNTech looks to close the purchase of its former rival CureVac for about $1.25 billion. GSK will receive $370 million upfront, with another $130 million on the closing of the the wake of the race to develop Covid-19 vaccines, drugmakers launched multiple lawsuits against one another over alleged patent infringement. The litigation has spanned across Europe and the US, pitting rival vaccine manufacturers against one another in the worked with CureVac to develop Covid-19 vaccines but they failed, losing out to quicker, nimbler rivals. Last year, the two companies restructured their collaboration, with GSK paying CureVac up to $1.4 billion for the full rights to mRNA flu and Covid-19 vaccines it was developing with the German will also receive 1% on royalties of future Pfizer-BioNTech sales of flu, Covid-19 and related combination mRNA vaccines in the US. Once BioNTech completes the purchase of CureVac, GSK will also receive 1% of royalties from future sales outside the the settlement ends CureVac's litigation with Pfizer and BioNTech, it doesn't mean the same for GSK. The British drugmaker said it will continue its litigation against BioNTech and Pfizer for what it alleges is infringement of its patents.